Paul
Blanchfieldruns the isotope company.

The Route

The résumé is legible in a particular way. Duke undergraduate in economics. Five years at McKinsey serving pharma and healthcare clients. Then across the fence into industry, which is the McKinsey-alum move that separates the people who like the deck from the people who want to run the P&L. Blanchfield wanted the P&L.

At Shire and then Takeda, from roughly 2013 to 2019, he did what people who want to become a CEO do at a big pharma company. He was Chief of Staff to the CEO, which is the seat next to the throne, where you learn how a $30 billion company actually makes its decisions. He was Head of Corporate Strategy, which is where you learn what those decisions cost. He was General Manager for Nordics-Baltics, which is a small enough region to run entirely and a large enough one to fail publicly. He was Head of U.S. Immunology, which is where you learn to be a commercial operator in the biggest market in the world.

Then Lantheus. Lantheus is a Boston-adjacent company - it's technically in North Billerica - that most consumers have never heard of and most oncologists know intimately. It makes medical imaging agents and, increasingly, radiotherapeutics. Its stock roughly quintupled between 2020 and 2024 on the back of a diagnostic agent called Pylarify. Blanchfield ended up as President, overseeing Commercial, R&D, Medical, Technical Operations, and Quality. That is essentially everything except finance and the CEO's calendar.

You do not leave the president chair at Lantheus for the CEO chair at a 32-person startup unless you think the startup will not stay at 32 for long.

The Company He Now Runs

Alpha-9 was founded to develop targeted radiopharmaceuticals across a range of tumor targets. Its keyword cloud, if you consult its public materials, contains most of the jargon of the field: chelator development, peptide chemistry, fluorine-labeling, binder/linker modification, dose optimization, target engagement, actinium-225 supply. This is a technical company. The specialty of the technical company, historically, is that it needs an operator to become a commercial company. That is the standard biotech CEO transition, and it is essentially what Alpha-9's board has just bought.

One of Alpha-9's assets, disclosed publicly, is a radiotherapeutic targeting MC1R - a receptor on melanoma cells - which entered a first-in-human trial and was written up in the trade press. Others are earlier. The pipeline mixes alpha emitters and beta emitters, chelator work, and peptide-based tumor-targeting molecules. The company works, according to its own materials, on "bespoke" molecules, which is a word biotech companies use when they mean "we make our own instead of licensing them in."

There is also a supply-chain story. Actinium-225 is one of the rarest useful things in the world. It is made in a small number of national laboratories and increasingly at newer accelerator facilities. The demand curve for it is going up steeply. The supply curve is going up too, but not as fast. A radiopharma company that cannot secure actinium supply is a radiopharma company with a very expensive PowerPoint. This is one of the things Blanchfield's tenure at Lantheus, which lives and dies by isotope logistics, will have prepared him for.

The Reading of the Man

There is not much of a public Blanchfield to read. He does not appear to be an active tweeter. There is no personal Substack, no widely circulated podcast appearance, no long-form magazine profile. This is normal for a certain kind of pharma executive - the operator, as distinct from the founder or the scientist. What is on the record is the press release, and the press release is telling in its restraint. It says he is honored. It says the team is talented. It says the pipeline is first- and best-in-class. The words "first and best-in-class" appear in essentially every biotech CEO-appointment press release ever issued, which is why they carry roughly the informational weight of "delicious" in a menu description.

What the résumé says, though, is specific. Chief of Staff to the CEO of Shire is a role you do not get by being loud. Head of U.S. Immunology at Takeda is a role you do not survive by being cautious. General Manager Nordics-Baltics is a role that requires you to be, among other things, willing to spend a lot of time in Copenhagen. And an MA in Education from Stanford, tucked in next to the MBA, is a credential biotech CEOs almost never have and rarely admit to. Somebody, at some point, was interested in how people learn things.

The Bet

The market for Blanchfield's kind of hire is tight. Every radiopharma company right now - and there are more of them each quarter - wants a CEO who has (a) run a real commercial organization in the space, (b) understands isotope supply as an operational problem and not a footnote, and (c) can plausibly walk into a large pharma company's business-development meeting and be taken seriously. There are perhaps thirty people in the world who tick all three boxes. Blanchfield ticks them.

What Alpha-9's board is buying, effectively, is optionality. If the pipeline works, Blanchfield can commercialize it. If part of the pipeline works and part does not, he can carve out the part that does and structure a deal. If none of it works but the platform - the chemistry, the chelators, the targeting expertise - is valuable, he can license it. If a large pharma buyer arrives with a check, he has run the kind of processes that let a small company get the terms it wants instead of the terms it is offered. Each of these outcomes is a different job. Each job requires a different day.

None of these outcomes is guaranteed. Clinical-stage biotech is, statistically, an industry that kills companies. Radiopharma has an additional variable of physical infrastructure - if you cannot get the isotope, the drug is a thought experiment. Blanchfield takes over during an unusually good moment for the category. Category moments end. That is one of the things a Chief of Staff to the CEO learns quickly.

The interesting thing, from a distance, is not that a well-credentialed executive took a well-funded CEO job. That happens every week. The interesting thing is what the specific résumé - McKinsey, Shire, Takeda, Lantheus - reads like when you hold it up against a specific company at a specific moment. It reads like a fit. Whether it turns out to be one is a question for the readouts.

Frequently Asked